|
2024
|
Invention
|
Methods of treating atopic dermatitis.
The present disclosure is directed to methods of treating... |
|
2022
|
Invention
|
Methods of treating atopic dermatitis. The present disclosure is directed to methods of treating ... |
|
|
Invention
|
Methods of treating atopic dermatitis with anti il-13 antibodies. The present disclosure is direc... |
|
|
P/S
|
Pharmaceutical preparations for use in the treatment of leukemia, auto inflammatory disease, auto... |
|
2021
|
Invention
|
Crystalline forms of ozanimod and processes for preparation thereof. The present disclosure relat... |
|
|
Invention
|
Sphingosine 1 phosphate receptor modulators.
Compounds are provided having the structure of Form... |
|
|
Invention
|
Sphingosine 1 phosphate receptor modulators. Compounds are provided having the structure of Formu... |
|
2020
|
Invention
|
Cxcr3 receptor agonists. Compounds are provided having the structure of the following Formula I:
... |
|
|
Invention
|
Sphingosine 1 phosphate receptor modulator.
A compound is provided having following structure Co... |
|
|
Invention
|
Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof. ... |
|
2019
|
P/S
|
Pharmaceutical preparations for use in the treatment of
leukemia, auto inflammatory disease, aut... |
|
|
P/S
|
Pharmaceutical preparations for use in the treatment of autoimmune disease, multiple sclerosis an... |
|
2018
|
Invention
|
Crystalline form of ozanimod hydrochloride, and processes for preparation thereof. The present di... |
|
|
Invention
|
Sphingosine 1 phosphate receptor agonists for neuroprotection. Methods of treating conditions for... |
|
|
Invention
|
Glp-1 receptor modulators. 4 are as defined herein.
|
|
|
Invention
|
Novel glp-1 receptor modulators. Compounds are provided that modulate the glucagon-like peptide 1... |
|
2017
|
Invention
|
Dimethylaminoethanol salt of a glp-1 receptor modulator. Crystalline 2-hydroxy-N,N-dimethylethana... |
|
|
Invention
|
Compounds and methods for treating lupus. Methods for treatment of systemic lupus erythematosus (... |
|
|
Invention
|
Glp-1 receptor modulators. ” represents either or both the R and S form of the compound):
1, n, ... |
|
|
Invention
|
Crystal form of ozanimod hydrochloride and processes for preparation therefor. The present disclo... |
|
|
Invention
|
Cxcr3 receptor agonists.
Compounds are provided having the structure of the following Formula I:... |
|
|
Invention
|
Cxcr3 receptor agonists. Compounds are provided having the structure of the following Formula I: ... |
|
|
P/S
|
Pharmaceutical preparations for use in the treatment of leukemia, auto inflammatory disease, name... |
|
|
P/S
|
Pharmaceutical preparations for use in the treatment of leukemia, auto inflammatory disease namel... |
|
|
Invention
|
Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis. Compounds ... |
|
2016
|
Invention
|
Glp-1 receptor modulators. ” represents either or both the R and S form of the compound):
5, n, ... |
|
|
P/S
|
Pharmaceutical preparations for use in the treatment of
leukemia, autoinflammatory disease, auto... |
|
|
P/S
|
Pharmaceutical preparations for use in the treatment of beta thalassemia and myelodysplastic synd... |
|
|
Invention
|
Glp-1 receptor stabilizers and modulators. Compounds that bind the glucagon-like peptide 1 (GLP-1... |
|
2015
|
Invention
|
Glp-1 receptor modulators. Compounds are provided that modulate the glucagon-like peptide 1 (GLP-... |
|
|
Invention
|
Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis. Compounds that selec... |
|
2014
|
Invention
|
Selective heterocyclic sphingosine 1 phosphate receptor modulators.
Compounds that selectively m... |
|
|
Invention
|
Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith.
Compoun... |
|
2012
|
Invention
|
Selective heterocyclic sphingosine 1 phosphate receptor modulators. Compounds that selectively mo... |
